Plain-English translation of NCT07174687 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 2 โ Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a one-year study testing whether a medication called can slow the progression of geographic atrophy, a condition where the light-sensitive cells in the center of the retina gradually break down, leading to vision loss. Half of the participants will take by mouth once daily, and half will take a placebo (a pill with no active medication). Researchers will track changes in the size of the damaged area using specialized eye imaging.
Geographic atrophy is a serious form of age-related macular degeneration that currently has no proven treatment to slow its progression. This medication was originally developed for diabetes, but early research suggests it may help protect the eye and slow vision loss โ an idea worth testing in people with this condition.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
You will take one pill by mouth every day for 12 months โ either the study medication or a placebo. You will visit the study center for a baseline visit and a final visit at 12 months to have your eyes imaged and tested with specialized equipment that measures the size and characteristics of the damaged area. The study is double-blind, meaning neither you nor the research team will know which pill you are taking until the study ends.
AI-generated summary from trial data ยท Aug 29, 2026 ยท Not medical advice
United States